Affimed Therapeutics (AFMD) AFM13-NK Data May Bode Well for Solid Tumors - Piper Sandler
Tweet Send to a Friend
Piper Sandler analyst Do Kim reiterated an Overweight rating and $7.00 price target on Affimed Therapeutics (NASDAQ: AFMD) after updated ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
